PTK2 and pancreatic neoplasm: The small molecule GSK2256098 (GlaxoSmithKline) can inhibit PDAC cell growth by targeting FAK Y397 phosphorylation [134], and it is under clinical evaluation in combination with trametinib (a MEK1/2 inhibitor) treatment for advanced pancreatic cancer (NCT02428270).